Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207770 | 0.92 | GAA (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL6983056 | 0.89 | GAA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10207669 | 0.89 | GAA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL16948227 | 0.87 | GAA (0.38) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL16946140 | 0.87 | GAA (0.38) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18233777 | 0.85 | ALDH1A1 (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13124943 | 0.84 | GAA (0.36) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10373036 | 0.83 | GAA (0.36) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL9532061 | 0.83 | PRKCA (0.38) | GAAL3MBTL1KMT2ALMNAMEN1 | |
| SCHEMBL13124951 | 0.83 | PRKCA (0.38) | GAAL3MBTL1KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111408-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY AND HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-116534984-A | Method for treating pollutants by special microorganism reinforced microbial fuel cell | 江苏理工学院 | 2023-08-04 | — | — | CN | disclosed |
| WO-2021004547-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1 | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2021-01-14 | — | — | WO | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-2990405-B1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
| EP-2990405-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | Suzhou Zelgen Biopharmaceuticals Co. Ltd. (CN) | 2016-03-02 | — | — | EP | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014173291-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | 苏州泽璟生物制药有限公司 (CN) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | GAA 1685/4885MGAM 3377/4885SI 3529/4885 |
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, PDCD1 | GAA 1730/4885MGAM 3745/4885SI 1721/4885 |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | GAA 1685/4885MGAM 3377/4885SI 3529/4885 |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | DCK, DPYD, BRAF | GAA 1530/4885MGAM 3513/4885SI 1674/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | GAA 1685/4885MGAM 3377/4885SI 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.